What Causes Temporomandibular Joint Problems?
Discussion
The mandible normally grows in a symmetric downward and forward movement relative to the skull base. The condyle is the primary growth center. “The mandible is unique in that its 2 joints and growth centers function together as a single unit.” It is the last bone in the body to reach skeletal maturity. The mandible and its growth are important for maxillary growth and therefore many problems that affect the mandible affect the facial and skulls structures as well. These growth problems can be relatively insidious and therefore may need monitoring over longer periods of time such as patients with unde...
Source: PediatricEducation.org - May 27, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Should Wearables Target the & #039;Walking Well & #039; Before Going After a Medical Indication?
As recently as 2017, there was still more talk than action in the clinical wearables market and the majority of companies making wearable devices were pursuing health and wellness applications first, with plans to pursue a medical device indication after the consumer version of the product took off.
In some cases that is still true, but a panel of experts speaking at BIOMEDevice Boston 2019 highlighted a new trend. One that might seem unexpected for those who have been following the wearables market for the past five years or longer.
"I'm in the medical space, I'm used to dealing with CGMs [continuous glucose monitors] whi...
Source: MDDI - May 20, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Digital Health Software Source Type: news
DUOGLOBE Interim Results: Intestinal Gel Cuts PD'Off' Time DUOGLOBE Interim Results: Intestinal Gel Cuts PD'Off' Time
Researchers release additional results looking at levodopa-carbidopa intestinal gel to help lessen motor fluctuations and dyskinesia in people with advanced Parkinson ' s disease.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 6, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Management of Antipsychotic-Induced Tardive Dyskinesia Management of Antipsychotic-Induced Tardive Dyskinesia
Newer generation antipsychotics have reduced, but not eliminated, the risk of antipsychotic-induced tardive dyskinesia. What are the best management options for this debilitating adverse effect?Current Opinion in Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 22, 2019 Category: Consumer Health News Tags: Psychiatry Journal Article Source Type: news
Explaining the Renewed Interest in Tardive Dyskinesia Explaining the Renewed Interest in Tardive Dyskinesia
According to Dr Jeffrey Lieberman, it ' s not science but marketing that ' s driving the rise in TD coverage.Medscape Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 25, 2019 Category: Consumer Health News Tags: Psychiatry Commentary Source Type: news
Paroxysmal kinesigenic dyskinesia presented following concussion - Cottrill N, McCully B, Payne M.
[Abstract unavailable]
Language: en... (Source: SafetyLit)
Source: SafetyLit - December 25, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Adaptive Deep-Brain Stimulation Promising for Parkinson's Adaptive Deep-Brain Stimulation Promising for Parkinson's
Researchers test a DBS device in development that automatically senses and adjusts delivery of electrical stimulation, aiming to avoid dyskinesia and other side effects of current technology.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 12, 2018 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Report: Apple update improves Watch ’ s ability to track movement disorders
Apple (NSDQ:AAPL) is upping its diagnostic game with the Apple Watch yet again, adding the ability to more accurately detect tremors for individuals with Parkinson’s Disease, according to a CNBC report.
The company is updating the bio-sensor laden smartwatch to make it easier for researchers to differentiate between random movement and the shakes and dyskinesia experienced by Parkinson’s patients while they’re under treatment from medication, according to the report.
The announcement came last week at Apple’s WWDC developer conference, CNBC reports.
The updated movement disorder API will allow developers to improv...
Source: Mass Device - June 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News mHealth (Mobile Health) Patient Monitoring Apple Source Type: news
Anticholinergic medication for antipsychotic-induced tardive dyskinesia.
Antipsychotic (neuroleptic) medication is used extensively to treat people with serious mental illnesses. However, it is associated with a wide range of adverse effects, including movement disorders. Because of this, many people treated with antipsychotic medication also receive anticholinergic drugs in order to reduce some of the associated movement side-effects. However, there is also a suggestion from animal experiments that the chronic administration of anticholinergics could cause tardive dyskinesia.
To determine whether the use or the withdrawal of anticholinergic drugs (benzhexol, benztropine, biperiden, orphenadr...
Source: Current Awareness Service for Health (CASH) - May 25, 2018 Category: Consumer Health News Source Type: news
Benzodiazepines for antipsychotic-induced tardive dyskinesia
Tardive dyskinesia (TD) is a disfiguring movement disorder, often of the orofacial region, frequently caused by using antipsychotic drugs. A wide range of strategies have been used to help manage TD, and for those who are unable to have their antipsychotic medication stopped or substantially changed, the benzodiazepine group of drugs have been suggested as a useful adjunctive treatment. However, benzodiazepines are very addictive.
To determine the effects of benzodiazepines for antipsychotic-induced tardive dyskinesia in people with schizophrenia, schizoaffective disorder, or other chronic mental illnesses. (Source: Curr...
Source: Current Awareness Service for Health (CASH) - May 25, 2018 Category: Consumer Health News Source Type: news
Insightec seeks Parkinson ’ s indication in Japan for Exablate Neuro
Insightec said this week it submitted an application for pre-market approval to the Japanese Pharmaceuticals and Medical Devices Agency seeking an indication for its Exablate Neuro to treat advanced Parkinson’s Disease in patients suffering from mobility, rigidity or dyskinesia.
The Israel-based company’s Exablate Neuro device uses high-intensity, focused ultrasound to thermally ablate targeted tissue, guided by continuous magnetic resonance imaging; the procedure can be performed non-invasively through an intact skull.
“Insightec is committed to supporting research that extends the applications and po...
Source: Mass Device - May 18, 2018 Category: Medical Devices Authors: Fink Densford Tags: Neurological Regulatory/Compliance Ultrasound INSIGHTEC Source Type: news
Boston Scientific touts 1-year data on Vercise DBS in Parkinson ’ s
This study meets a new level of rigor in evaluating the effectiveness of a DBS system,” coordinating principal investigator Dr. Jerrold Vitek, of the University of Minnesota Medical School, said in prepared remarks. “The double-blind design gives us confidence that the improvements in patients on time with good symptom control, as evaluated by the diary data, are an objective measure of the outcomes and suggests patients will benefit from the Vercise System.”
Vercise won CE Mark approval in the European Union to treat essential tremor in 2014. FDA approval to treat Parkinson’s followed last December, ...
Source: Mass Device - April 24, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Neuromodulation/Neurostimulation Boston Scientific Parkinson's disease Source Type: news
Positive Long-term Results for Tardive Dyskinesia Drug Positive Long-term Results for Tardive Dyskinesia Drug
Long-term efficacy and safety/tolerability outcomes are positive in older patients with tardive dyskinesia treated with valbenazine, according to pooled analyses from several phase 3 trials.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 3, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news
New study explains how your brain helps you learn new skills
(Gladstone Institutes) Researchers from the Gladstone Institutes uncovered how a special type of neuron improves the efficiency of procedural learning. They initially wanted to show how the specialized brain cells, called fast-spiking interneurons, cause movement disorders, such as Tourette's syndrome, dystonia, and dyskinesia. As it turns out, that isn't the case. But their work led them to an even greater discovery. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 8, 2018 Category: International Medicine & Public Health Source Type: news
Non-profit to accelerate development of potential new Parkinson's drug
(Parkinson's UK) UK charity, Parkinson's UK is partnering with US biotech Neurolixis in a $1 million deal to accelerate the development of a potential cure for dyskinesia -- a severe side effect of common Parkinson's medication. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 24, 2018 Category: International Medicine & Public Health Source Type: news
